About anemia in inflammation (AI) & kidney disease

Modus is evaluating sevuparin’s potential as a treatment option in disorders with high levels of the iron regulating hormone hepcidin, such as anemia in chronic kidney disease (CKD) and certain other chronic inflammation disorders, as part of its longstanding collaboration with the University of Brescia. 

The robust results from preclinical cellular and animal models as well as human subjects demonstrate sevuparin’s ability to suppress hepcidin at clinically safe dose levels and provide strong evidence of its ability to modulate hepcidin expression. This positions sevuparin as a promising candidate for addressing high hepcidin disorders such as anemia of chronic diseases.